Last updated July 22, 2026
Key finding
Periodontal parameters were improved in both groups (p < 0.05).
This study investigated the effects of periodontal treatment on the risk of cerebral infarction in patients with type 2 diabetes mellitus, finding significant reductions in inflammatory markers.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of periodontal treatment on the risk of cerebral infarction in patients with type 2 diabetes mellitus, finding significant reductions in inflammatory markers.
This study highlights the importance of oral health in managing chronic conditions like diabetes. By improving periodontal health, clinicians may not only enhance patients' dental outcomes but also reduce the risk of serious complications such as cerebral infarction, emphasizing a holistic approach to diabetes care.
Unclear changes in apolipoprotein A1, C1, and alpha-1-B glycoprotein levels. Limited generalizability due to specific population characteristics. Potential confounding factors not measured in the study.
Published in
Publication details and source links for this paper.
Aulia R, Azusa T, Kumiko M, et al. Effects of Periodontal Treatment on the Risk of Cerebral Infarction in Patients with Type 2 Diabetes Mellitus. European Journal of Dentistry. 2024;19(3):749-757. doi:10.1055/s-0044-1795115
Periodontal inflammation score improved significantly in the intervention group (p < 0.05).
IL-6 levels decreased by 0.4 pg/mL in the intervention group (p = 0.02).
Complement C3 levels decreased by 8.5 mg/dL in the intervention group (p = 0.02).
Alpha-2-antiplasmin levels decreased by 0.6 mg/dL in the intervention group (p = 0.01).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Scaling with local antibiotic adjunct (Periofol 2%) and Alpha-1-B glycoprotein levels, Alpha-2-antiplasmin levels, Apolipoprotein A1, and 4 more.
This study contributes evidence to
Primary intervention
Scaling with local antibiotic adjunct (Periofol 2%)
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
7
Evidence pairs
58
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
Scaling with local antibiotic adjunct (Periofol 2%) → Alpha-1-B glycoprotein levels
Scaling with local antibiotic adjunct (Periofol 2%) → Alpha-1-B glycoprotein levels
Scaling with local antibiotic adjunct (Periofol 2%) → Alpha-2-antiplasmin levels
Scaling with local antibiotic adjunct (Periofol 2%) → Alpha-2-antiplasmin levels
Scaling with local antibiotic adjunct (Periofol 2%) → Apolipoprotein A1
Scaling with local antibiotic adjunct (Periofol 2%) → Apolipoprotein A1
Scaling with local antibiotic adjunct (Periofol 2%) → Apolipoprotein C1 levels
Scaling with local antibiotic adjunct (Periofol 2%) → Apolipoprotein C1 levels
Scaling with local antibiotic adjunct (Periofol 2%) → Apolipoprotein C3 change
Scaling with local antibiotic adjunct (Periofol 2%) → Apolipoprotein C3 change
Scaling with local antibiotic adjunct (Periofol 2%) → Interleukin-6 (IL-6)
Scaling with local antibiotic adjunct (Periofol 2%) → Interleukin-6 (IL-6)
Scaling with local antibiotic adjunct (Periofol 2%) → Periodontal inflamed surface area
Scaling with local antibiotic adjunct (Periofol 2%) → Periodontal inflamed surface area
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Scaling with local antibiotic adjunct (Periofol 2%) and Alpha-1-B glycoprotein levels, Scaling with local antibiotic adjunct (Periofol 2%) and Alpha-2-antiplasmin levels.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Alpha-1-B glycoprotein levels
Measures Alpha-1-B glycoprotein levels as a key outcome.
All studies measuring Alpha-2-antiplasmin levels
Measures Alpha-2-antiplasmin levels as a key outcome.
All studies on Scaling with local antibiotic adjunct (Periofol 2%)
Contributes to Scaling with local antibiotic adjunct (Periofol 2%) evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Scaling with local antibiotic adjunct (Periofol 2%) appears to improve Alpha-2-antiplasmin levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Alpha-2-antiplasmin levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Scaling with local antibiotic adjunct (Periofol 2%) appears to improve Apolipoprotein C3 change.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Apolipoprotein C3 change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Scaling with local antibiotic adjunct (Periofol 2%) appears to improve Interleukin-6 (IL-6).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Interleukin-6 (IL-6)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Scaling with local antibiotic adjunct (Periofol 2%) appears to improve Periodontal inflamed surface area.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Periodontal inflamed surface area
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
